Last updated: February 10, 2026
Inspra (eplerenone) is a selective aldosterone receptor blocker used to treat heart failure and hypertension. The drug was developed by Pfizer, which holds the primary patent and manufacturing rights. Key points about suppliers include manufacturing, licensing, and distribution channels.
Who Are the Main Suppliers and Manufacturers?
Pfizer:
- Original developer and primary supplier of Inspra.
- Manufacturing facilities based in the United States and other countries.
- Maintains global supply chain for the drug through its own production sites and authorized contract manufacturing organizations (CMOs).
Contract Manufacturing Organizations (CMOs):
- Pfizer outsources some production to third-party CMOs to meet global demand.
- Notable CMOs involved in pharmaceutical active ingredient (API) production and final drug formulation.
- Examples include companies like Zhejiang Hisun Pharmaceutical Co. and others engaged in API manufacturing globally.
Licensing and Distribution Partners:
- Pfizer employs licensed distributors worldwide to supply Inspra to markets outside the United States.
- Distribution channels are regulated strictly, with some regional limitations based on licensing agreements.
Patent and Market Exclusivity
- Pfizer’s patent for Inspra expired in the U.S. in 2024, opening the door to generic manufacturers.
- In other regions, patent status and exclusivity depend on local patent law, with generics entering markets upon patent expiration or invalidation.
Generic Suppliers
- Following patent expiration, multiple generic companies have entered the market.
- Notable generic manufacturers include Sun Pharmaceutical Industries, Teva Pharmaceuticals, and Mylan (now Viatris).
- These companies produce APIs and final formulations that meet regulatory standards to supply various markets.
Regulatory Status and Approvals
- The drug is approved by regulatory agencies including FDA (U.S.) and EMA (Europe) for approved indications.
- Suppliers must comply with Good Manufacturing Practices (GMP) to manufacture and distribute Inspra and generics.
Market Dynamics
- The global Inspra market involves Pfizer as the main supplier in branded form until patent expiry.
- Post-patent expiration, the market has seen increased competition from generics, reducing prices and expanding access in emerging markets.
- Supply chain disruptions can arise from manufacturing issues, regulatory changes, or shifts in licensure agreements.
Summary Table of Key Suppliers and Market Terms
| Entity |
Role |
Key Markets |
Status |
| Pfizer |
Original patent holder, primary supplier |
Global, especially developed markets |
Branded, patent-protected |
| Zhejiang Hisun Pharmaceutical |
Contract manufacturer (API) |
China, Asia, some global markets |
Produces for Pfizer and generics |
| Sun Pharmaceutical Industries |
Generic API and finished dosage forms |
India, Asia, emerging markets |
Post-patent entry |
| Teva Pharmaceuticals |
Generic API and dosage forms |
U.S., Europe, global |
Post-patent entry |
| Mylan (Viatris) |
Generic manufacturer |
Global |
Post-patent entry |
Key Takeaways
- Pfizer remains the primary supplier, especially in branded forms, until patent expiry.
- Generics became significant players after patent expiration in the U.S. and other regions.
- Multiple API producers supply the market, with China and India playing major roles.
- Distribution relies on licensed partners, with regulatory compliance critical for supply continuity.
- Market competition is increasing, affecting pricing and availability.
FAQs
1. Who currently supplies Inspra in the U.S.?
Pfizer supplies the branded version until patent expiration, after which generic manufacturers like Teva and Mylan can legally produce and distribute the drug.
2. Are there generic versions of Inspra?
Yes. Several companies obtained approval for generic eplerenone following Pfizer’s patent expiration, increasing supply options domestically and internationally.
3. Does Inspra have any authorized contract manufacturers?
Yes. Pfizer partners with contract manufacturers primarily in China and India for API production and finished drug formulation.
4. What regulatory factors influence supply chain stability?
GMP compliance, patent laws, regional licensing agreements, and manufacturing capacity influence the supply of Inspra and its generics.
5. How does patent expiry affect the supply market?
Patent expiry permits generic manufacturers to enter the market, leading to increased competition, lower prices, and broader global distribution.
References
- Pfizer Inc. Inspra (eplerenone) product information. (2022). Pfizer.com
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (2023). FDA.gov
- Market data and patent expiration info. IMS Health, GlobalData, 2022-2023.
- Generic drug approvals. FDA and EMA databases, 2022–2023.
[1] Pfizer. Inspra (eplerenone). https://www.pfizer.com
[2] U.S. Food and Drug Administration. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
